Yahoo Finance • 6 days ago
[Recession graph] J Studios * Valneva SE (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]) is cutting its 2025 full-year sales and revenue guidance as a result of the US FDA's August decision to revoke [https://seekingalpha.com/news/... Full story
Yahoo Finance • 6 days ago
New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business developmentCompany adjusts 2025 financial guidance and provides key business updates Saint-Her... Full story
Yahoo Finance • 6 days ago
Le nouvel accord de prêt diffère le remboursement de la dette du premier trimestre 2026 au quatrième trimestre 2030, à un taux d’intérêt inférieur au précédent, et offre la possibilité d’obtenir davantage de financement pour des activités... Full story
Yahoo Finance • 12 days ago
Long-lasting antibody persistence was comparable in older (65+) and younger adults Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya Saint-Herblain (Fran... Full story
Yahoo Finance • 12 days ago
Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultes La durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie épidémique comme le chikungu... Full story
Yahoo Finance • 18 days ago
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pom... Full story
Yahoo Finance • 24 days ago
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Valneva and would like to disc... Full story
Yahoo Finance • last month
(RTTNews) - Valneva SE(VALN, VLA.PA) announced positive immunogenicity and safety results from its ongoing Phase 2 clinical trial of the Lyme disease vaccine candidate, VLA15. The data show a strong anamnestic immune response and a favorab... Full story
Yahoo Finance • last month
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring Committee (DMC), co... Full story
Yahoo Finance • last month
Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappelForte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le... Full story
Yahoo Finance • 2 months ago
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Valneva SE (NASDAQ: VALN) regarding possible violations of federal securities laws. Investors... Full story
Yahoo Finance • 2 months ago
[Woman trading stock with mobile app in front of stock exchange screen.] Guido Mieth Stock futures edged lower Monday morning as Wall Street kicked off the final trading week of August with focus on Nvidia’s upcoming earnings. Here are s... Full story
Yahoo Finance • 2 months ago
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the pr... Full story
Yahoo Finance • 2 months ago
Saint-Herblain (France), le 18 août 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à d... Full story
Yahoo Finance • 2 months ago
* Valneva press release [https://seekingalpha.com/pr/20196941-valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates] (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]): 1H net loss of €20.8 million compared to... Full story
Yahoo Finance • 2 months ago
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (Fra... Full story
Yahoo Finance • 2 months ago
Chiffre d’affaires de 97,6 millions d’euros contre 70,8 millions d’euros au premier semestre 2024Trésorerie de 161,3 millions d’euros à fin juin 2025Poursuite des avancées cliniques et réglementaires Confirmation des perspectives 2025 Sai... Full story
Yahoo Finance • 2 months ago
[Medical form with diagnosis Chikungunya in a hospital.] designer491/iStock via Getty Images Valneva SE (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]) said on Thursday that the FDA has lifted its pause on the use of its chikungunya... Full story
Yahoo Finance • 2 months ago
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and... Full story
Yahoo Finance • 2 months ago
Saint Herblain (France), le 7 août 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la levée de l’arrêt temporaire de l’agence de santé américaine Food and Drug Administrati... Full story